The Lohr lab explores tumor evolution and drug resistance in various types of cancer, with a particular interest in multiple myeloma. We use "liquid biopsy" approaches to obtain circulating tumor cells (CTCs) and cell-free DNA (cfDNA) combined with innovative DNA- and RNA-sequencing technologies and computational analysis, as tools to gain insight into tumor biology and translate these findings into novel targeted therapies.
These strategies yield potential targets that may be exploited for overcoming drug resistance. For mechanistic exploration of these candidate targets we use a wide variety of tools, which span the spectrum from biochemistry to mouse models. These approaches will lead to a better understanding of the dynamic molecular and genetic changes of cancer over time, which will be crucial for effective precision medicine.